Key result
CHF 2363 exerted potent antiaggregating and vasorelaxant activity via nitric oxide release and increased cyclic GMP levels, with no in vitro cross-tolerance with glyceryl trinitrate.
Why the study?
Does CHF 2363 inhibit platelet aggregation and induce vasorelaxation in preclinical models?
Population
Human platelet-rich plasma, rubbed endothelium rabbit aortic rings, and rat aortic strips
Comparison
CHF 2363 (4-ethoxy-3-phenylsulphonylfuroxan) vs Sodium nitroprusside and glyceryl trinitrate (GTN)
Design
Preclinical
Authors
Loading...
Preclinical activity without GTN cross-tolerance supports human testing of CHF 2363; leaves open clinical efficacy and safety.
Does CHF 2363 inhibit platelet aggregation and induce vasorelaxation in preclinical models?
CHF 2363 is a novel furoxan derivative that acts as a potent NO donor, inhibiting platelet aggregation and inducing vasorelaxation without cross-tolerance to GTN in preclinical models.
Civelli et al. (1996) studied this question. CHF 2363 vs. sodium nitroprusside and glyceryl trinitrate was evaluated on Platelet aggregation inhibition and vasorelaxant activity. CHF 2363 exerted potent antiaggregating and vasorelaxant activity via nitric oxide release and increased cyclic GMP levels, with no in vitro cross-tolerance with glyceryl trinitrate.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: